论文部分内容阅读
1早期的血脂干预研究20世纪60年代,Framingham流行病学研究明确证实血脂异常是动脉粥样硬化性心血管疾病的重要危险因素,由此揭开了与高胆固醇血症抗争的序幕。一般推测,既然血液胆固醇水平升高可以增加冠状动脉性心脏病(冠心病)的发病风险及其致死致残率,那么通过药物降低胆固醇水平将使此类患者显著获益。然而,在此后的30年间所完成的一系列降脂治疗试验却未能证实这一假设。始于1973年的奥斯陆一级预防
An Early Study of Serum Lipid Interference In the 1960s, the Framingham epidemiological study clearly confirmed that dyslipidemia is an important risk factor for atherosclerotic cardiovascular disease, thus opening the curtain on the fight against hypercholesterolemia. It is generally speculated that, since elevated blood cholesterol levels may increase the risk of coronary heart disease (CHD) and its morbidity to death, reducing cholesterol levels through medication will benefit these patients significantly. However, a series of lipid-lowering treatment trials completed over the next 30 years failed to confirm this hypothesis. Beginning in 1973 with primary prevention in Oslo